Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

GSK misses survival endpoint with Tykerb-Herceptin pairing

01.06.2014 / Fierce Pharma

Glaxo announced at ASCO on Sunday that in a Phase III study<span style="font-size: 13px;">, Tykerb and Herceptin failed to improve&nbsp;</span>disease-free survival in HER2-positive early breast cancer patients over<span style="font-size: 13px;">&nbsp;Herceptin on its own.</span>

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: